Minmin (Mimi) Yen is passionate about using innovative solutions to reduce global health inequities. She is the CEO & Co-Founder of PhagePro, a global health biotech startup based in Massachusetts, U.S. that is developing bacteriophage-based solutions to antibiotic resistance in low- and middle-income countries.
Her work is focused on commercializing innovative, alternative antimicrobials for emerging markets through collaborative in-country partnerships and multi-sectoral, inclusive strategies. PhagePro’s first product is an orally administered, cold chain-independent bacteriophage cocktail that will be taken prophylactically to disrupt cholera transmission. For her work, Minmin has received a number of honors and fellowships, including the MIT Technology Review 35 Innovators Under 35, Boston Business Journal Women Who Mean Business Award, Termeer Foundation Fellowship, and the Atlantic Council Millennium Fellowship. In addition, she has served on U.S. National Institutes of Health Study Sections as an ad hoc reviewer and has been an invited speaker for bacteriophage and antimicrobial resistance conferences both nationally and around the world.
Minmin obtained her Bachelor of Science in Biological Engineering from the Massachusetts Institute of Technology, her Ph.D. in Molecular Microbiology from Tufts University, and her Master of Public Health in Program Management and Global Health from Boston University.